Two top medical research and biotech innovators in New Zealand have announced a partnership that will supercharge cancer research while providing new levels of health data privacy.

Amaroq Therapeutics is elevating its research pipeline by partnering with GeneCrypt, a startup which uses privacy preserving technology to unlock value in genetic data. 

GeneCrypt has worked closely with Unitec's Cybersecurity Lab to develop a pragmatic and computationally friendly solution to this very real problem. The goal is simply to provide an unbreachable level of security over patient data while researchers and precision medicine clinicians focus on curing disease.  

The collaboration with GeneCrypt will allow Amaroq to supercharge its existing research pipeline by accessing more patient datasets. This will expand Amaroq's opportunities for drug discovery and business development.

GeneCrypt's technology uses an end-to-end secure pipeline which means patients can be confident their data will not be exposed at any point during the process, and researchers can use existing datasets that are relevant to their research without access to all the information present in the genome.

To date, Amaroq has received $14 million in investment led by the life science investor, Brandon BioCatalyst along with Otago Innovation Ltd, NZ Innovation Booster and Cure Kids Ventures.